2023 annual financial data
Inhibikase Therapeutics 2023 Operating margin
Direct answer
Operating margin was -7,712.01%.
Operating income was -20,089,792 USD and net income was -19,028,883 USD.
Operating cash flow was -18,085,043 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 260,500 USD
- Operating income
- -20,089,792 USD
- Net income
- -19,028,883 USD
- Operating cash flow
- -18,085,043 USD